Janssen Announces Collaboration with Gilead to Develop PREZISTA®-based Single-tablet Regimen for the Treatment of People Living with HIV
Cork, Ireland (ots/PRNewswire) - -- Two Companies to also Collaborate on the Further Development of Complera(R), Marketed as Eviplera(R) in the European Union -- Janssen R&D Ireland (Janssen) announced today an amendment to its existing agreement with Gilead Sciences, Inc. (Gilead), initially established in 2011, ...
mehr